Author: Amela-Cortes, Marian ; Lundstroem-Stadelmann, Britta ; Autier, Brice ; Plaisse, Charleen ; Aninat, Caroline ; Preza, Matias ; Verger, Alexis ; Samson, Michel ; Chollet-Krugler, Marylène ; Dion, Sarah ; Brandhonneur, Nolwenn ; Manuel, Christelle

Alveolar echinococcosis (AE) is a severe disease caused by the infection with the larval stage of Echinococcus multilocularis, the metacestode. As there is no actual curative drug therapy, recommendations to manage AE patients are based on radical surgery and prophylactic administration of albendazole or mebendazole during 2 years to prevent relapses. There is an urgent need for new therapeutic strategies for the management of AE, as the drugs in use are only parasitostatic, and can induce toxicity. This study aimed at developing a drug delivery system for mefloquine, an antiparasitic compound which is highly active against E. multilocularis in vitro and in experimentally infected mice. We formulated mefloquine-loaded PLGA-PEG-COOH (poly-(lactic-co-glycolic acid)) nanoparticles that exhibit stable physical properties and mefloquine content. These nanoparticles crossed the outer acellular laminated layer of metacestodes in vitro and delivered their content to the inner germinal layer within less than 5 min. The in vitro anti-echinococcal activity of mefloquine was not altered during the formulation process. However, toxicity against hepatocytes was not reduced when compared to free mefloquine. Altogether, this study shows that mefloquine-loaded PLGA-PEG-COOH nanoparticles are promising candidates for drug delivery during AE treatment. However, strategies for direct parasite-specific targeting of these particles should be developed.

11 Sep 2024·Revista Espanola de Quimioterapia

Refractory Enterobius vermicularis infection in an elderly woman: Mebendazole or albendazole?

Letter

Author: Carranza-Rodríguez, C ; Tosco-Nuñez, T ; Pérez-Arellano, J L ; Suárez-Hormiga, J ; Jaén-Sánchez, N

03 Sep 2024·The American journal of tropical medicine and hygiene

A Mixed-Methods Evaluation of Mainstreaming Mass Drug Administration for Schistosomiasis and Soil-Transmitted Helminthiasis in Four Districts of Nigeria

Article

Author: Ugbadamu, Paul ; Griswold, Emily ; Amayat, Goodluck James ; Poko, Happiness ; Emukah, Emmanuel C. ; Danboyi, Jacob ; Rakers, Lindsay ; Ndudi, Okocha ; Eigege, Abel ; Coalson, Jenna ; Anighoro, Vincent ; Miri, Emmanuel S. ; Gallagher, Jayden Pace ; Unukopia, Regina Ese ; Mancha, Bulus ; Noland, Gregory S. ; Otabor, Esther ; Dikedi, Philomena ; Gwong, Christiana Davou ; Dagwa, Philemon

ABSTRACT.:

In Nigeria, mass drug administration (MDA) for schistosomiasis (SCH) and soil-transmitted helminthiasis (STH) has often been coordinated with other programs that receive greater external funding. As these programs reach stop MDA milestones, SCH and STH programs will likely need to transition implementation, or “mainstream,” to domestic support. A mixed-methods study was conducted in four districts before (2021) and after (2022) mainstreaming to evaluate its impact on MDA coverage. Household surveys were done in 30 villages per district pre- and post-mainstreaming. All selected communities were eligible for STH treatment; around a third were eligible for SCH treatment. Mass drug administration was primarily conducted in schools. A total of 5,441 school-aged children were included in pre-mainstreaming and 5,789 were included in post-mainstreaming. Mass drug administration coverage was heterogeneous, but overall, mebendazole coverage declined nonsignificantly from 81% pre-mainstreaming to 76% post-mainstreaming (P = 0.09); praziquantel coverage declined significantly from 73% to 55% (P = 0.008). Coverage was significantly lower among unenrolled children or those reporting poor school attendance in nearly every survey. For the qualitative component, 173 interviews and 74 focus groups were conducted with diverse stakeholders. Respondents were deeply pessimistic about the future of MDA after mainstreaming and strongly supported a gradual transition to full government ownership. Participants formulated recommendations for effective mainstreaming: clear budget allocation by governments, robust and targeted training, trust building, and comprehensive advocacy. Although participants lacked confidence that SCH and STH programs could be sustained after reductions in external support, initial results indicate that MDA coverage can remain high 1 year into mainstreaming.

News (Medical) associated with Mebendazole

14 Feb 2024

·www.sciencedaily.com

Controlling root growth direction could help save crops and mitigate climate change

Scientists have determined how the well-known plant hormone ethylene is crucial in controlling the angle at which roots grow. The findings can be used to engineer plants and crops that withstand the environmental stresses of climate change and drought, and perhaps to create plants that remove carbon dioxide from the atmosphere and store it deep underground to help mitigate climate change. Above ground, plants stretch toward the sun. Below ground, plants tunnel through the earth. As roots soak up water and nutrients from surrounding soil, they grow and stretch to develop distinct root system architectures. The root system architecture determines whether roots remain in the shallow soil layers or grow steeper and reach deeper soil layers. Root systems are central to plant survival and productivity, determining the plant's access to nutrients and water and, therefore, the plant's ability to withstand nutrient depletion and extreme weather like drought. Now, Salk scientists have determined how a well-known plant hormone is crucial in controlling the angle at which roots grow. The study, published in Cell Reports on February 13, 2024, is the first time the hormone, called ethylene, has been shown to be involved in regulating lateral root angles that shape root systems -- making the findings a revelation for plant scientists optimizing root systems. Researchers in Salk's Harnessing Plants Initiative now plan to target the ethylene signaling pathway in their efforts to engineer plants and crops that can withstand the environmental stresses of climate change and drought, as well as removecarbon dioxide from the atmosphere and store it deep underground to help mitigate climate change. "Deep roots lead to more durable carbon storage in the soil and can make plants more resistant to drought, so the ability to control how deep roots grow is really exciting for scientists looking to engineer better root systems," says senior author Wolfgang Busch, professor, executive director of the Harnessing Plants Initiative, and Hess Chair in Plant Science at Salk. "We're especially excited that the pathway we found is conserved across many types of plants, meaning our findings can be widely applied to optimize root architecture in all land plants, including food, feed, and fuel crops." Environmental factors -- like average rainfall or abundance of certain nutrients -- can influence the shape of a plant's root system. The angle at which roots grow produces different results in overall root architecture, with horizontal root angles creating a shallower root system and vertical root angles creating a deeper root system. But scientists did not understand clearly how these root angles were being determined on a molecular level. Plant hormones like auxin and cytokinin have been connected to the angle of root growth in the past, but the mechanisms of that connection have remained poorly understood. In searching for molecules and pathways that were involved in setting the angle of root growth, the team genetically screened Arabidopsis thaliana -- a small flowering weed in the mustard family -- for root system changes in response to thousands of molecules. "We noticed this molecule called mebendazole was causing the roots to grow more horizontally," says first author Wenrong He, a former postdoctoral researcher in Busch's lab. "When we looked for what target proteins or pathways mebendazole was interacting with to have this effect, we discovered it was ethylene signaling -- and ethylene playing such an essential role in root system architecture was really intriguing." The team observed that genes throughout the ethylene signaling pathway were activated in response to mebendazole, and, in turn, the pathway was carrying out the resulting changes in root growth. Biochemical investigation of this relationship revealed that mebendazole inhibits the activity of a protein kinase called CTR1. This enzyme negatively regulates ethylene signaling, in turn promoting a shallow root system. "Since ethylene signaling is a widely conserved process in land plants, targeting the ethylene pathway is a very promising technique for root system engineering," says Busch. "Hopefully, now we'll be able to use this tool to make crop species more resilient, and to create Salk Ideal Plants® that sequester more carbon underground to assist in the fight against climate change." The newfound implication of ethylene in root system architecture inspires new questions, including whether another molecule exists that -- unlike mebendazole -- makes root systems deeper, or if there are specific genes in the already well-cataloged ethylene signaling pathway that can be targeted most effectively to promote deeper roots in crops and Salk Ideal Plants. Other authors include Hai An Truong, Ling Zhang, Min Cao, and Kaizhen Zhong of Salk; Neal Arakawa of UC San Diego; Yao Xiao of the Scripps Research Institute; and Yingnan Hou of UC Riverside and Shanghai Jiao Tong University in China. The work was supported by Salk's Harnessing Plants Initiative, a Salk Women & Science Special Award, a Pioneer Fund Postdoctoral Scholar Award, the National Institutes of Health (NIH-NCI CCSG: P30 CA01495, NIH-NIA San Diego Nathan Shock Center P30 AG068635), Chapman Foundation, and Helmsley Charitable Trust.

20 Oct 2023

·www.jnj.com

Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model

Chicago, Illinois (October 20, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today promising data from a Phase 2a human challenge study evaluating JNJ-1802, a first-in-class oral antiviral in development for the prevention of dengue. The data showed that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo, and is safe and well-tolerated. The data were announced at the American Society of Tropical Medicine & Hygiene Annual Meeting in Chicago, Illinois.JNJ-1802 is the first antiviral to show such activity in humans during a clinical trial. The compound has advanced to a community-based field study to establish efficacy against circulating dengue serotypes in a real-world setting. The study is being conducted in 30+ sites in 10 countries, including Philippines, Thailand, Peru, Brazil and Colombia.“Climate change threatens to put more people at risk of dengue, yet the world lacks the necessary tools to combat this significant health challenge,” said Ruxandra Draghia-Akli, M.D., Ph.D., Global Head, Global Public Health R&D at Janssen Research & Development, LLC. “For over a decade, we have been committed to following the science to bring forward new solutions for dengue and this new data is an encouraging step forward to addressing the expanding impact of climate change on human health.”The two-center, randomized, double-blind, placebo-controlled human challenge study evaluated the antiviral activity, safety and pharmacokinetics of different dosing regimens – low, medium or high – of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults. All participants received daily doses of JNJ-1802 or a placebo over 26 days, during which they were challenged with DENV-3 on day 5. All participants were monitored over 85 days. The study found dose-dependent antiviral effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo and was safe and well-tolerated.“The promising results of JNJ-1802 to date offer the hope that science will be able to deliver against this threat as more and more communities are impacted worldwide,” said Marnix Van Loock, Ph.D., Lead for Emerging Pathogens, Global Public Health R&D at Janssen Pharmaceutica NV. “Dengue requires global action, and we are proud to collaborate alongside partners around the world in advancing the development of this compound to its next phase.”This study follows data published in Nature in March 2023, which showed that JNJ-1802 provides strong protection against dengue in non-human primates and mice, and a Phase 1 first-in-human clinical study showing that the antiviral was safe and well-tolerated.Janssen thanks its supporting partners including the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of Clinical Research (DCR and Office of Clinical Research Policy and Regulatory Operations (OCRPRO) for their collaboration in conducting this trial.A New Tool to Fight a Growing ThreatThe development of a dengue antiviral is critically important to global health. Over half the world’s population currently lives in areas where dengue is endemic. Dengue fever impacts at least 400 million annually, sickening an estimated 100 million and killing thousands, with more going undiagnosed or misdiagnosed.Changes in climate are exacerbating the crisis, lengthening the infection season and allowing the mosquito that carries the virus to spread beyond its native regions. In 2023, countries like Bolivia, Peru and Bangladesh have already reported some of their worst outbreaks on record, and countries like the U.S., Spain and France are seeing a rise of locally acquired cases for the first time.Research and development (R&D) against dengue has proven challenging due to four globally circulating serotypes and there are currently no therapeutics and only two licensed vaccines limitedly available. Investment in antivirals, which do not require cold chain and can induce immunity in just days, is sorely needed to diversify the prevention toolbox to slow down outbreaks and limit epidemic-levels of cases.Johnson & Johnson’s Commitment to DengueJohnson & Johnson has been investing in dengue R&D for over a decade. The Company is also collaborating closely with academic partners to bolster local R&D. In June 2022, Johnson & Johnson launched its Satellite Center for Global Health Discovery at Duke-NUS in Singapore, which is focused on accelerating early-stage discovery research to address the growing challenge of flaviviruses, including dengue.These efforts are part of Johnson & Johnson’s more than 15-year legacy working to address the burden of neglected tropical diseases (NTDs), a group of about 20 communicable diseases that together affect more than 1.7 billion people in 149 countries around the world. In 2022, the Company joined the global community to endorse the Kigali Declaration on Neglected Tropical Diseases, pledging to continue to donate up to 200 million doses annually of mebendazole through 2025 to tackle intestinal worms and advance novel R&D programs to discover new medications needed to beat leprosy and dengue.You can learn more about our efforts to beat NTDs, including dengue, by visiting JNJ.com/NTDs.  About the Janssen Pharmaceutical Companies of Johnson & JohnsonAt Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.Learn more at www.janssen.com. Follow us at @JanssenUS and @JanssenGlobal. Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/. Cautions Concerning Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding dengue fever, flavivirus and neglected tropical diseases. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Pharmaceutica NV and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Pharmaceutica NV nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Phase 2VaccineClinical ResultPhase 1

17 Mar 2023

·www.jnj.com

Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice. The first-in-class antiviral, which was shown to be safe and well tolerated in a Phase 1 first-in-human clinical study, is now progressing into Phase 2 clinical studies for the prevention and treatment of dengue. The new data indicate JNJ-1802 is effective against all four of the dengue serotypes in mouse models and provides strong protection against two tested serotypes (DENV-1 and -2) in non-human primates. These findings build on research published in Nature in 2021 that first identified the novel mechanism of action from the same chemical series as JNJ-1802. The mechanism of action prevents the interaction between two viral proteins (NS3 and NS4B), thereby stopping the ability of the virus to replicate. A similar mechanism of action was confirmed for JNJ-1802 with these new data. This new research, together with Phase 1 first-in-human data showing the compound to be safe and well-tolerated, is supportive of further clinical development of JNJ-1802 for both prophylaxis and treatment of dengue. “The unprecedented rise in dengue outbreaks throughout the past years offers a glimpse of what lies ahead as climate change continues to put more people and communities at risk of dengue,” said Ruxandra Draghia-Akli, M.D., Ph.D., Global Head, Global Public Health R&D at Janssen Research & Development, LLC. “We know an antiviral will be critical to addressing the unmet needs today and tomorrow, and we are committed to developing our breakthrough compound to expand the toolset available to prevent and treat dengue.” Janssen thanks its strategic partners in the research and development of its dengue compound, including the KU Leuven Rega Institute, the KU Leuven Centre for Drug Design and Discovery (CD3), Department of Virology at the Biomedical Primate Research Centre, Department of Infectious Diseases at Heidelberg University, Sealy Institute for Vaccine Sciences at the University of Texas Medical Branch Health (UTMB), Unité des Virus Émergents at Aix-Marseille University and the Walter Reed Army Institute of Research. The Growing Global Dengue Threat Dengue is a significant and growing global health challenge. As many as 400 million people contract the dengue virus each year, and the resulting illness is one of the leading causes of hospitalization among children in countries in Latin America and Asia. Despite the global burden of dengue, and the fact that reinfection is possible due to the presence of four dengue serotypes, there are no therapeutics available to treat the disease and only a limited number of prevention options have been approved. “The promising results of JNJ-1802 to date offer the hope that science will be able to deliver against this threat as more and more communities are impacted worldwide,” said Marnix Van Loock, Ph.D., Lead for Emerging Pathogens, Global Public Health R&D at Janssen Pharmaceutica NV. “Dengue requires global action and we are proud to collaborate alongside partners here in Europe and around the world in advancing the development of this compound to its next phase.” The dengue challenge is likely to grow in the coming years. In 2022, countries like Singapore, Nepal and Bangladesh experienced some of their worst outbreaks on record, while non-endemic countries like France and the United States reported some of their first, locally-acquired cases, part of a broader trend of increasing zoonotic outbreaks linked to climate change. Strengthening Johnson & Johnson’s Enduring Commitment to Neglected Tropical Diseases (NTDs) Johnson & Johnson’s work against dengue is one part of a larger, more than 15-year legacy working to address the burden of NTDs, a group of about 20 communicable diseases that affect more than 1.7 billion people in 149 countries around the world. In 2022, the Company joined the global community to endorse the Kigali Declaration on Neglected Tropical Diseases, pledging to continue to donate up to 200 million doses annually of mebendazole through 2025 to tackle intestinal worms and advance novel R&D programs to discover new medications needed to beat leprosy and dengue. In addition to developing JNJ-1802, Johnson & Johnson is working to holistically strengthen R&D for dengue, including through novel R&D approaches and leveraging emerging technology. To support the Company’s clinical development program, Johnson & Johnson is using artificial intelligence (AI) to forecast dengue hotspots and build predictive models for dengue incidence to accelerate trial recruitment and site sourcing. Data from the project was recently presented at the 2022 Annual Meeting of the American Society of Tropical Medicine and Hygiene. Additionally, the Company launched the Satellite Center for Global Health Discovery at Duke-NUS Medical School in Singapore in June 2022, which is focused on accelerating early-stage, discovery research to address the growing challenge of flaviviruses, including dengue. The Satellite Center, the first to be established in Asia, was launched as part of the Company’s broader efforts to expand the global network for R&D and bolster local R&D, building on a longstanding collaboration with Duke-NUS. You can learn more about Johnson & Johnson’s efforts to beat NTDs, including dengue, by visiting JNJ.com/NTDs. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism and Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal and @JanssenUS. Janssen Research & Development, LLC and Janssen Pharmaceutica NV are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.

Clinical Study

100 Deals associated with Mebendazole

External Link

KEGG	Wiki	ATC	Drug Bank
D00368	Mebendazole	P02CA01	DB00643

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ascariasis	US	Janssen Pharmaceuticals, Inc.	28 Jun 1974
Enterobiasis	US	Janssen Pharmaceuticals, Inc.	28 Jun 1974
Hookworm Infections	US	Janssen Pharmaceuticals, Inc.	28 Jun 1974
Trichuriasis	US	Janssen Pharmaceuticals, Inc.	28 Jun 1974

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Helminthiasis	Phase 3	ET	Janssen Research & Development LLC	01 Dec 2014
Helminthiasis	Phase 3	RW	Janssen Research & Development LLC	01 Dec 2014
Parasitic Diseases	Phase 3	TZ	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Feb 2010
Anemia	Phase 3	PK	Johns Hopkins Bloomberg School of Public Health	01 Apr 2004
Brain Stem Glioma	Phase 2	US	Janssen Pharmaceuticals, Inc.	22 Oct 2013
Diffuse Intrinsic Pontine Glioma	Phase 2	US	Janssen Pharmaceuticals, Inc.	22 Oct 2013
Glioblastoma Multiforme	Phase 2	US	Janssen Pharmaceuticals, Inc.	22 Oct 2013
Gliosarcoma	Phase 2	US	Janssen Pharmaceuticals, Inc.	22 Oct 2013
Low grade glioma	Phase 2	US	Janssen Pharmaceuticals, Inc.	22 Oct 2013
Optic Nerve Glioma	Phase 2	US	Janssen Pharmaceuticals, Inc.	22 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTRI/2018/01/011542 (BELOB, ASCO2022) Manual	Phase 2	Recurrent Glioblastoma	-	lomustine+Mebendazole	gnleeypjeg(aqwprtygva) = cpeovwftqn xmpkbvnele (thtydfdzhl, 29.6 - 59.2) View more	Negative	02 Jun 2022
				temozolomide+Mebendazole	gnleeypjeg(aqwprtygva) = asvesyosec xmpkbvnele (thtydfdzhl, 22.3 - 51) View more
NCT03925662 (Pubmed \| Life Sci) Manual	Phase 3	Metastatic Colorectal Carcinoma	40	Mebendazole + bevacizumab + FOLFOX4	pjhnakqcrw(hfbfjogxxg): P-Value = 0.063 View more	Positive	03 Apr 2022
				Bevacizumab + FOLFOX4 + placebo
NCT03995680 (CHEW_MEB_PEMBA, CTgov)	Phase 2	Hookworm Infections	397	Mebendazole (Chewable Tablet of Mebendazole)	nnelyrdmzf(aqgkathgdc) = oqnaitvahl mqahuniaxe (hzcbmmhzcz, kighdrzkoo - qjxcvneqhd) View more	-	20 Jul 2020
				Mebendazole (Swallowable Tablet of Mebendazole)	nnelyrdmzf(aqgkathgdc) = uypdyuwxnl mqahuniaxe (hzcbmmhzcz, dagtdledwu - haakswgozr) View more
NCT03245398 (CTgov)	Phase 4	Hookworm Infections	186	one of the two regimens of mebendazole (Single Dose of Mebendazole)	hkhpyqitle(jbmyknnknu) = clnezoeezj xfdjglcqcy (xbjzdsttmf, wdjtzewroa - eekakrcebh)	-	17 Jun 2019
				one of the two regimens of mebendazole (Multiple Dose of Mebendazole)	hkhpyqitle(jbmyknnknu) = ocypzyjpfb xfdjglcqcy (xbjzdsttmf, upvowvytia - qqpkzlofvv)
NCT03245398 (Pubmed) Manual	Phase 4	Hookworm Infections	185	Single dose mebendazole	rrlpqpxwab(guovxozjbw) = sowghmfznc owajzityfl (jahjmaghor ) View more	Positive	01 Jul 2018
				Multiple dose mebendazole	rrlpqpxwab(guovxozjbw) = hthwogtgdw owajzityfl (jahjmaghor ) View more
NCT02034162 (CTgov)	Phase 3	Helminthiasis	295	placebo (Double-blind Placebo)	rrwaajbuxj(lhekodvyck) = idmnbltdyc cwyzwvqlhv (mfxvmsljsi, logbtaudti - wufqimvlaj) View more	-	04 Nov 2016
				Mebendazole (Double-blind Mebendazole 500 mg)	rrwaajbuxj(lhekodvyck) = ykkyavhwps cwyzwvqlhv (mfxvmsljsi, jvaymwwdbu - ccbitotths) View more
NCT01379326 \| NCT01087099 (Pubmed \| PLoS Negl Trop Dis) Manual	Phase 4	Helminthiasis	250	Mebendazole 500 mg	qemskzncqd(ujgcelpnob) = ittfxzezmq wzldyjsnbd (cxfeddfqvs, 95.8 - 99.5) View more	Positive	01 Oct 2014
				Albendazole 400 mg	qemskzncqd(ujgcelpnob) = vztxpahnjw wzldyjsnbd (cxfeddfqvs, 99.0 - 100) View more
NCT01350271 (CTgov)	Phase 3	Helminthiasis	214	Placebo (Placebo)	atrhrsvkqz(hgcpaoetor) = gcsugoblur syclsadoaq (xfbehdgdag, tvrkpujtoa - gplzhxbsnm) View more	-	22 Apr 2013
				Mebendazole polymorph A (Mebendazole Polymorph A and C 500 mg)	atrhrsvkqz(hgcpaoetor) = zavvvczmnl syclsadoaq (xfbehdgdag, ckuyemmldm - chmleqrjgq) View more
ERS2012 Manual	Not Applicable	Persistent asthma total IgE \| Ascaris-specific IgE	24	Mebendazole	geqtfgwphh(kfamkppggc) = uaplzhwgad pbftpkekvn (yepjagbgfb ) View more	Positive	01 Sep 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis